Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Bone Marrow Mononuclear Cell Therapy in DMD
NCT02241434Phase 1Withdrawn
- Sponsor
- NeuroGen Brain & Spine Institute
- Start
- Jan 2009
- Primary completion
- Jan 2016
- Countries
- 1
01
Overview
Phase 1, open-label trial of autologous bone marrow-derived mononuclear cell in Duchenne muscular dystrophy (DMD), sponsored by NeuroGen Brain & Spine Institute. Primary endpoint: Manual Muscle Testing at 1 year. Planned start Jan 2009; status: withdrawn.
02
Drugs
autologous bone marrow-derived mononuclear cell
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT02241434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02241434.